Thursday, 15 October 2026European Markets

FERM.CAS.MUN.CANNE And BAINS MER MONACO Have A High Dividend Yield And Return On Equity In The Resorts & Casinos Industry.

Loading stream...

(vianews) - ferm.cas.mun.canne (fcmc.pa) is among this list of stock assets with the highest dividend rate and return on equity on the resorts & casinos industry.

financial asset price forward dividend yield return on equity
ferm.cas.mun.canne (fcmc.pa) €1590.00 5% 3.89%
bains mer monaco (bain.pa) €103.00 1.22% 5.66%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ferm.cas.mun.canne (fcmc.pa)

5% forward dividend yield and 3.89% return on equity

société fermière du casino municipal de cannes operates casinos and hotels in france. the company operates 3 hotels with 565 rooms, suites, and cottages under the hôtel barrière le majestic, the hôtel barrière le gray d'albion, and the hôtel barrière le carl gustaf st-barth brands; and 2 casinos, including 350 slot machines and 38 games tables under the casino barrière croisette and casino barrière les princes brands. it also operates 8 restaurants, 9 bars, and 1 spa. the company was founded in 1919 and is based in cannes, france.

earnings per share

as for profitability, ferm.cas.mun.canne has a trailing twelve months eps of €60.1.

pe ratio

ferm.cas.mun.canne has a trailing twelve months price to earnings ratio of 26.46. meaning, the purchaser of the share is investing €26.46 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.89%.

yearly top and bottom value

ferm.cas.mun.canne's stock is valued at €1,590.00 at 17:40 est, way below its 52-week high of €1,810.00 and way higher than its 52-week low of €1,400.00.

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 11, 2023, the estimated forward annual dividend rate is 77 and the estimated forward annual dividend yield is 5%.

more news about ferm.cas.mun.canne.

2. bains mer monaco (bain.pa)

1.22% forward dividend yield and 5.66% return on equity

société anonyme des bains de mer et du cercle des étrangers à monaco operates in the gaming, hotels, and rental sectors in monaco. the company operates casinos; hotels; restaurants; lounge bars and nightclubs; wellness and leisure facilities; shows and concert halls; shopping centers; and meetings and events centers. it is also involved in the slot machines, table games, and other activities; and rental of residential properties, boutiques, and offices. in addition, the company offers catering services. the company was incorporated in 1863 and is headquartered in monaco.

earnings per share

as for profitability, bains mer monaco has a trailing twelve months eps of €3.63.

pe ratio

bains mer monaco has a trailing twelve months price to earnings ratio of 28.37. meaning, the purchaser of the share is investing €28.37 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.66%.

dividend yield

according to morningstar, inc., the next dividend payment is on oct 10, 2023, the estimated forward annual dividend rate is 1.2 and the estimated forward annual dividend yield is 1.22%.

moving average

bains mer monaco's value is below its 50-day moving average of €105.58 and below its 200-day moving average of €104.64.

yearly top and bottom value

bains mer monaco's stock is valued at €103.00 at 17:40 est, way below its 52-week high of €115.00 and above its 52-week low of €98.20.

more news about bains mer monaco.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com